Catalent (NYSE:CTLT) Posts Quarterly Earnings Results, Misses Expectations By $0.18 EPS

Catalent (NYSE:CTLT) released its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18), Briefing.com reports. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. Catalent’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.10) earnings per share.

Catalent Stock Up 2.5 %

Shares of CTLT traded up $1.48 during trading hours on Wednesday, hitting $59.96. The stock had a trading volume of 3,400,612 shares, compared to its average volume of 2,045,490. The firm has a 50 day simple moving average of $60.03 and a 200-day simple moving average of $58.02. Catalent has a 1-year low of $32.38 and a 1-year high of $61.20. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. The firm has a market capitalization of $10.88 billion, a P/E ratio of -10.65, a price-to-earnings-growth ratio of 2.06 and a beta of 1.16.

Analysts Set New Price Targets

Several research firms have recently weighed in on CTLT. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. StockNews.com initiated coverage on shares of Catalent in a report on Saturday, October 12th. They set a “hold” rating on the stock. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Robert W. Baird reissued a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. Nine equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $59.83.

Insiders Place Their Bets

In related news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.31% of the company’s stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.